ANI Pharmaceuticals beats Q3 revenue estimates on Cortrophin demand

ANI Pharmaceuticals

07/11/2025 11:57

Overview

ANI Q3 2025 revenue grows 53.6% yr/yr, beating analyst expectations

Adjusted EPS for Q3 2025 beats consensus, reaching $2.04

Company raises 2025 revenue and adjusted EBITDA guidance, citing strong Rare Disease growth

Outlook

ANI raises 2025 total net revenue guidance to $854 mln - $873 mln

Company expects Rare Disease net revenues to be 50% of total in 2025

ANI anticipates 2025 adjusted non-GAAP EBITDA of $221 mln - $228 mln

Result Drivers

CORTROPHIN GEL GROWTH - Cortrophin Gel net revenues increased 93.8% yr/yr due to increased demand and expanded sales force across specialties

ILUVIEN REVENUE PRESSURE - ILUVIEN net revenues were pressured by reduced Medicare access but showed progress in label transition adoption

GENERICS GROWTH - Generics net revenues increased 20.6% yr/yr driven by a successful partnered generic launch

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$227.80 mln
$211.04 mln (8 Analysts)
Q3 Adjusted EPS
Beat
$2.04
$1.75 (8 Analysts)
Q3 EPS
$1.13
Q3 Net Income
$26.30 mln
Q3 Adjusted EBITDA
$59.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for ANI Pharmaceuticals Inc is $103.00, about 12.4% above its November 6 closing price of $90.23

The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release: ID:nGNX60lmXM

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)